KAIMRC’S Second Therapeutics Discovery Conference
subject: rare diseases, coronavirus, infectious diseases, drug discovery and development, academic drug discovery, KAIMRC
description: Following the success of our first therapeutic discovery conference in 2017 and the selection of King Abdullah International Medical Research Centre (KAIMRC) as the first Phase 1 clinical site in the Kingdom of Saudi Arabia, we organized our second conference in partnership with leading institutions in academic drug discovery, which included the Structural Genomic Constorium (Oxford, UK), Fraunhofer (Germany) and Institute Material Medica (China); the participation of members of the American Drug Discovery Consterium; European Biotech companies; and local pharma companies, SIPMACO and SudairPharma. In addition, we had European and Northern American venture capital experts attending and presenting at the conference. The purpose of the conference was to bridge the gap between biotech, pharma and academia regarding drug discovery and development. Its aim primarily was to: (a) bring together world experts on academic drug discovery to discuss and propose new approaches to discover and develop new therapies; (b) establish a permanent platform for scientific exchange between academia and the biotech and pharmaceutical industries; (c) entice national and international investors to consider funding drugs discovered in academia; (d) educate the population about the causes of diseases, approaches to prevent them from happening and their cure; (e) attract talent to consider the drug discovery track for their studies and career. During the conference, we discussed the unique academic drug discovery disrupting business models, which can make their discoveries easily accessible in an open source mode. This unique model accelerates the dissemination of knowledge to all world scientists to guide them in their research. This model is aimed at bringing effective and affordable medicine to all mankind in a very short time. Moreover, the program discussed rare disease targets, orphan drug discovery, immunotherapy discovery and process, the role of bioinformatics in drug discovery, anti…
creator: Theam Soon Lim, Majid Alfadhel, Ahmed Alaskar, Mo Li, Sheraz Gul, Ahmed Bakillah, Bader Aldebasi, Salam Massadeh, Adel Nefzi, Mohamed Boudjelal, Tlili Barhoumi, Bandar Alghanem, Bahauddeen M Alrfaei, Atef Nehdi, Manal Alaamery, Zeyad Alehaideb, Jahad Alghamdi, Mohammed Al-Assiri, Nimer Mehyar, Mai Al Ajaji, Barrak Al Somaie, Yosra Boudjelal, Ibrahim Bushnak, Imadul Islam, Lamis Mouyes, Wyatt Yue
source: Proceedings
publisher: MDPI AG
date: 2020
identifier: DOI: 10.3390/proceedings2020043006
coverage: General Works